Search company, investor...

Trinity Biosystems

Founded Year



Bridge | Alive

Total Raised


Last Raised

$7.5M | 14 yrs ago

About Trinity Biosystems

Trinity Biosystems is developing a platform technology for the delivery of peptides across intact mucosal surfaces. The initial therapeutic applications of the technology will focus on vaccines, where animal testing has demonstrated the potential to induce both systemic and mucosal immunity following delivery of various antigens. The company's first product to enter trials will be a vaccine for the prevention of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) patients. Subsequent products will address other infectious diseases and the company will also be exploring the potential of applying the technology to the oral delivery of other biopharmaceuticals. Despite the continued discovery of novel peptides for the treatment and prevention of human disease, many applications suffer because the optimal delivery technology remains a key missing link. Trinity is developing technology capable of transporting proteins, peptides and other macromolecules across intact mucosal barriers using endogenous epithelial cell pathways. This technology not only overcomes current limitations associated with protein and peptide transport, but also provides targeted delivery to specific cells of the body.

Headquarters Location

1490 O’Brien Drive Suite A

Menlo Park, California, 94025,

United States


Missing: Trinity Biosystems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Trinity Biosystems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Trinity Biosystems Patents

Trinity Biosystems has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Clusters of differentiation, Polymer chemistry, Molecular biology, G protein coupled receptors


Application Date


Grant Date



Related Topics

Transcription factors, Clusters of differentiation, Polymer chemistry, Molecular biology, G protein coupled receptors



Latest Trinity Biosystems News

Trinity Biosystems raises $7.5M bridge to treat endocrine disorders

Jul 9, 2013

Trinity Biosystems raises $7.5M bridge to treat endocrine disorders November 9, 2009 8:56 AM Camille Ricketts 0 Trinity Biosystems , maker of a drug that can treat certain endocrine disorders, has brought in $7.5 million in bridge funding from Amgen Ventures, Life Science Partners, Lilly Ventures, Sanderling Ventures and SR One, according to Dow Jones VentureWire. Based in Menlo Park, Calif., the company has raised about $33.75 million since its first round of financing in 2004. Trending Research

Trinity Biosystems Frequently Asked Questions (FAQ)

  • When was Trinity Biosystems founded?

    Trinity Biosystems was founded in 2002.

  • Where is Trinity Biosystems's headquarters?

    Trinity Biosystems's headquarters is located at 1490 O’Brien Drive, Menlo Park.

  • What is Trinity Biosystems's latest funding round?

    Trinity Biosystems's latest funding round is Bridge.

  • How much did Trinity Biosystems raise?

    Trinity Biosystems raised a total of $28.5M.

  • Who are the investors of Trinity Biosystems?

    Investors of Trinity Biosystems include Sanderling Ventures, SR One, Amgen Ventures, Life Science Angels, Lilly Ventures and 4 more.

  • Who are Trinity Biosystems's competitors?

    Competitors of Trinity Biosystems include TheraVida, Promedior, Curemark, Melinta Therapeutics, Intra-Cellular Therapies and 11 more.

Compare Trinity Biosystems to Competitors


TheraVida develops therapeutic drugs intended for the treatment of hyperhidrosis. Its products help healthcare providers to treat urological disorders and improve the lives of patients. The company was founded in 2005 and is based in Chapel Road, North Carolina.

Paloma Pharmaceuticals

Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.


Curemark is a research-driven biotechnology company that develops and markets products to fulfill needs in neurological medicine. The company is committed to improving the quality of life for children and adults with neurological disorders by providing safe, effective and clinically proven solutions. The company's flagship product is focused on treating children with autism. Curemark was is based in Rye, New York.


NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


Excelimmune is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. This next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.